Evidence map›Paper›PMID 30898877›Full record

ArticleThe Journal of biological chemistry2019

Leukodystrophy-associated

Karine Choquet, Diane Forget, Elisabeth Meloche, Marie-Josée Dicaire, Geneviève Bernard, Adeline Vanderver, Raphael Schiffmann, Marc R Fabian, Martin Teichmann, Benoit Coulombe and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Molecular basis of neurodegeneration in a mouse model ofbioRxiv : the preprint server for biology · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. RNA Polymerases I and III in development and disease.Seminars in cell & developmental biology · 2023
    Review
  16. A Chinese patient withFrontiers in neurology · 2023
    Article
  17. Biallelic pathogenic variants inFrontiers in neurology · 2023
    Article
  18. Article
  19. tRNA dysregulation and disease.Nature reviews. Genetics · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Karine ChoquetFrom the Department of Human Genetics, McGill University, Montréal, Québec H3A 0C7, Canada.
Diane Forgetthe Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec H2W 1R7, Canada.
Elisabeth Melochethe Montréal Neurological Institute, McGill University, Montréal, Québec H3A 2B4, Canada.
Marie-Josée Dicairethe Montréal Neurological Institute, McGill University, Montréal, Québec H3A 2B4, Canada.
Geneviève BernardFrom the Department of Human Genetics, McGill University, Montréal, Québec H3A 0C7, Canada.
Adeline Vanderverthe Division of Neurology, Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania 19104.
Raphael Schiffmannthe Institute of Metabolic Disease, Baylor Research Institute, Dallas, Texas 75204.
Marc R Fabianthe Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec H3T 1E2, Canada.
Martin TeichmannINSERM U1212-CNRS UMR5320, Université de Bordeaux, Bordeaux, France, and.ORCID 0000-0002-5257-0510
Benoit Coulombethe Translational Proteomics Laboratory, Institut de Recherches Cliniques de Montréal (IRCM), Montréal, Québec H2W 1R7, Canada.
Bernard BraisFrom the Department of Human Genetics, McGill University, Montréal, Québec H3A 0C7, Canada.
Claudia L KleinmanFrom the Department of Human Genetics, McGill University, Montréal, Québec H3A 0C7, Canada, claudia.kleinman@mcgill.ca.
Montreal Neurological Institute and Hospital · CAJewish General Hospital · CAMontreal Clinical Research Institute · CABaylor Institute for Rehabilitation · USCentre National de la Recherche Scientifique · FRChildren's Hospital of Philadelphia · USMontreal Children's Hospital · CA

Funding

CIHR 201610PJT-377869CIHR MOP-126141CIHR MOP-G2-341146-159133-BRIDG
6 · The paper itself

Abstract

RNA polymerase III (Pol III) is an essential enzyme responsible for the synthesis of several small noncoding RNAs, a number of which are involved in mRNA translation. Recessive mutations in

Indexed as

MutationDown-RegulationGenes, RecessiveHeLa CellsHereditary Central Nervous System Demyelinating DiseasesHumansRNA, Long NoncodingRNA, MessengerRNA Polymerase IIIlong non-coding RNA BC200, humanPOLR3A protein, humanRNA, Long NoncodingRNA, MessengerRNA Polymerase IIIbrain cytoplasmic 200 RNA (BCYRN1)CRISPR/CasleukodystrophymyelinoligodendrocyteproteomicsRNA polymerase IIIRNA-seqtranscriptiontransfer RNA (tRNA)

Identifiers

PMID30898877
PMCPMC6509492
OpenAlexW2923924598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.